SELECTED PUBLICATIONS (Center physicians are bolded)
- Cresci S, Bach RG, Saberi S, Owens AT, Spertus JA, Hegde SM, Lakdawala NK, Nilles EK, Wojdyla DM, Sehnert AJ, Wang A. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation. 2023 Nov 14;. doi: 10.1161/CIRCULATIONAHA.123.065600. [Epub ahead of print] PubMed PMID: 37961906.
- Kim Y, Mastali M, Van Eyk J, Orav E, Vissing C, Day S, Raja AA, Russell M, Zahka K, Lever H, Pereira A, Murphy A, Canter C, Bach R, Wheeler M, Rossano J, Owens A, Bundgaard H, Benson L, Mestroni L, Taylor M, Patel A, Wilmot I, Thrush P, Soslow J, Becker J, Seidman C, and Ho C. Transforming Growth Factor-β Analysis of the VANISH Trial Cohort. Published ahead of print, 31 Mar 2023 https://doi.org/10.1161/CIRCHEARTFAILURE.122.010314 Circ Heart Fail. 2023;16
- Vissing CR, Axelsson Raja A, Day SM, Russell MW, Zahka K, Lever HM, Pereira AC, Colan SD, Margossian R, Murphy AM, Canter C, Bach RG, Wheeler MT, Rossano JW, Owens A, Benson L, Mestroni L, Taylor MRG, Patel AR, Wilmot I, Thrush P, Soslow JH, Becker JR, Seidman CE, Lakdawala NK, Cirino AL, McMurray JJV, MacRae CA, Solomon SD, Bundgaard H, Orav EJ, Ho CY, for the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators. Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy The VANISH Randomized Clinical Trial. JAMA Cardiol. 2023;8(11):1083–1088. doi:10.1001/jamacardio.2023.2808
- Wang A, Spertus JA, Wojdyla DM, Abraham TP, Nilles EK, Owens AT, Saberi S, Cresci S, Sehnert A, Lakdawala NK. Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension: Post-Hoc Analysis of the EXPLORER-HCM Trial. JACC Heart Fail. 2023 Oct 12;. doi: 10.1016/j.jchf.2023.07.030. [Epub ahead of print] PubMed PMID: 37855754.
- Johnson DY, Waken RJ, Fox DK, Hammond G, Joynt Maddox KE, Cresci S. Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States. J Am Heart Assoc. 2023 Jun 6;12(11):e029930. doi: 10.1161/JAHA.122.029930. Epub 2023 May 26. PubMed PMID: 37232238; PubMed Central PMCID: PMC10382014.
- Zytnick D, Heard D, Ahmad F, Cresci S, Owens AT, Shay CM. Exploring experiences of hypertrophic cardiomyopathy diagnosis, treatment, and impacts on quality of life among middle-aged and older adults: An interview study. Heart Lung. 2021 Nov-Dec;50(6):788-793. doi: 10.1016/j.hrtlng.2021.06.004. Epub 2021 Jul 2. PubMed PMID: 34225089.
- Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nat Med 2021;27, 1818–1824 (2021). https://doi.org/10.1038/s41591-021-01505-4.
- Moreno JD, Bach RG, Damiano RJ, Martinez SC, Cresci S. Phenylephrine Provocation to Evaluate the Cause of Mitral Regurgitation in Patients With Obstructive Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2021 May;14(5):e012656. doi: 10.1161/CIRCIMAGING.121.012656. Epub 2021 May 4. PubMed PMID: 33947204; PubMed Central PMCID: PMC8394282.
- Sherrid MV, Swistel DG, Olivotto I, Pieroni M, Wever-Pinzon O, Riedy K, Bach RG, Husaini M, Cresci S, Reyentovich A, Massera D, Maron MS, Maron BJ, Kim B. Syndrome of reversible cardiogenic shock and left ventricular ballooning in obstructive hypertrophic cardiomyopathy. J Am Heart Assoc. 2021. Oct 19;10(20):e021141. doi: 10.1161/JAHA.121.021141. Epub 2021 Oct 12. PMID: 34634917; PMCID: PMC8751867
- Husaini M, Baker JN, Cresci S, Bach R, LaRue SJ. Recurrent takotsubo cardiomyopathy in a patient with hypertrophic cardiomyopathy leading to cardiogenic shock requiring VA-ECMO. JACC Case Rep. 2020 Jun 17;2(7):1014-1018. doi: 10.1016/j.jaccas.2020.04.028. PMID: 34317404; PMCID: PMC8302101
- Bakir NH, MacGregor RM, Khiabani AJ, Musharbash FN, Schill MR, Sinn LA, Schuessler RB, Melby SJ, Gleva MJ, Damiano RJ Jr. Concomitant Cox-Maze IV and Septal Myectomy in Patients With Hypertrophic Obstructive Cardiomyopathy. Ann Thorac Surg. 2022 Jan;113(1):109-117. doi: 10.1016/j.athoracsur.2020.12.090. Epub 2021 Mar 1. PMID: 33662312; PMCID: PMC9536242.
- Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, Hegde SM, Jacoby D, Laksawala NK, Lester SJ, Ma Y, Marian AJ, Nagueh SF, Owens A, Rader F, Saberi S, Sehnert AJ, Sherrid MV, Solomon SD, Wang A, Wever-Pinzon O, Wong TC, Heitner SB. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020 Jun 2;75(21):2649-2660. doi: 10.1016/j.jacc.2020.03.064.PMID: 32466879
- Raja AA, Shi L, Day S, Russell M, Zahka K, Lever H, Colan SD, Margossian R, Hall K, Becker J, Jefferies JL, Patel A, Choudry L, Murphy AM, Canter C, Bach RG, Taylor M, Mestroni L, Wheeler M, BensonL, Owens A, Rossano J, Lin K, Pahl E, Pereira A, Bundgaard H, CirinoAL, McMurray JJV, MacRae CA, SolomonSD, Orav EJ, Ho CY. Baseline Characteristics of the VANISH Cohort. Circ Heart Fail. 2019;12:e006231, 2019/https://doi.org/10.1161/CIRCHEARTFAILURE.119.006231
- Musharbash FN, Schill MR, Hansalia VH, Schuessler RB, Leidenfrost JE, Melby SJ, Damiano RJ Jr. Minimally Invasive versus Full-Sternotomy Septal Myectomy for Hypertrophic Cardiomyopathy. Innovations (Phila). 2018 Jul/Aug;13(4):261-266. doi: 10.1097/IMI.0000000000000536. PMID: 30138243; PMCID: PMC6115297.
- Musharbash FN, Schill MR, Henn MC, Damiano RJ Jr. Minimally Invasive Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy Innovations (Phila). 2017 Nov/Dec;12(6):489-492. doi: 10.1097/IMI.0000000000000421. PMID: 29232302; PMCID: PMC5774662.
- Kotkar KD, Said SM, Dearani JA, Schaff HV. Hypertrophic obstructive cardiomyopathy: The Mayo Clinic experience. Ann Cardiothorac Surg. 2017 Jul;6(4):329-336. doi: 10.21037/acs.2017.07.03. PMID: 28944173; PMCID: PMC5602208.
- Nagueh S, Groves B, Schwartz L, Smith K, Wang A, Bach RG, Nielson C, Leya F, Buergler J, Rowe SK, Woo A, Maldonado YM, Spencer WH. Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: A multicenter North American registry, J Am Coll Cardiol, 2011;58(22);2322-2328.
- Bach, RG, Leach C, Milov S, Lindsay BD. Use of magnetic navigation to facilitate transcatheter alcohol septal ablation for hypertrophic obstructive cardiomyopathy. J Invas Cardiol. 2006:18;E176-E178.
- Kern MJ, Rajjoub H, Bach RG. Hemodynamic rounds series II: Hemodynamic effects of alcohol-induced septal infarction for hypertrophic obstructive cardiomyopathy. Cathet & Cardiovasc Interventions 1999; 47 (2):221-8.
- Kern MJ, Puri S. Donohue TJ, Bach RG. Hemodynamic rounds series II: Hemodynamics of dual-chamber pacing and Valsalva maneuver in a patient with hypertrophic obstructive cardiomyopathy. Cathet Cardiovasc Diagn 1998; 44 (4): 438-42.
- Bach RG, Kern MJ, Donohue TJ, Caracciolo EA, Aguirre FV, Moore JA. Interventional physiology: Dynamic systolic coronary flow reversal and hyperemia in left anterior descending coronary blood flow velocity during Valsalva maneuver in a patient with hypertrophic cardiomyopathy. Cathet Cardiovasc Diagn 1995; 34:67-71.